Bioharmony Therapeutics Inc., a New York-based startup developing lysins to fight bacterial infections, has secured support from Boehringer Ingelheim International GmbH to develop a therapy for multidrug-resistant Acinetobacter infections, a frequent cause of hospital-acquired pneumonia, blood and wound infections. Financial terms of the licensing and collaboration deal, arranged by Boehringer's Research Beyond Borders (RBB) program, were not disclosed.